Contact this trialFirst, we need to learn more about you.
Endothelin Receptor Antagonist
Combination Therapy + BPA for Thromboembolic Pulmonary Hypertension
Recruiting2 awardsPhase 3
Durham, North Carolina
This trial is testing a new combination therapy for inoperable or residual Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The therapy consists of two drugs, Riociguat and Macitentan, and balloon pulmonary angioplasty (BPA). The goal is to see if this new therapy can improve RV function and hemodynamics.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.